Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC 50 for human amylin 1 receptor...
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a...
From Devices to Experiences: TECNO Advances Its AIoT Ecosystem with OneLeap Interconnection Solution and Newly Launched Devices
BARCELONA, Spain, March 4, 2026 /PRNewswire/ -- TECNO, the AI-driven innovative technology brand, today announced an upgrade to its AIoT ecosystem at MWC. Central to this upgrade is TECNO OneLeap, a unified interconnection platform designed to...
UN Representatives from 17 Nations Visit BEDI to Study China's Leading Practices in Urban AI Industry Operations
BEIJING, Feb. 5, 2026 /PRNewswire/ -- The United Nations International Digital Economy Governance and Leadership Capacity Building Programme officially opened at Beijing Electronic Digital & Intelligence (BEDI). A delegation of 34 ministerial...
RSUPPORT Validates Top-Tier Security with ISO/IEC 27001 and 27017 Certifications
Asia's No.1 Remote Solutions Provider Once Again Recognized for Outstanding Security Excellence SEOUL, South Korea, Jan. 19, 2026 /PRNewswire/ -- RSUPPORT Co., Ltd., a leading provider of remote solutions, announced today that its Global R&D...
StarHub Earns its First-Ever 'A' Rating in CDP Climate Change Assessment
Recognised among global leaders in climate transparency and action SINGAPORE, Jan. 12, 2026 /PRNewswire/ -- StarHub has achieved its first-ever 'A' rating in CDP's 2025 Climate Change Assessment, marking the highest climate score StarHub has...
HR Asia Recognises Companies Leading Asia's Workplace Transformation
SINGAPORE, Jan. 12, 2026 /PRNewswire/ -- Organized by Business Media International, the HR Asia Best Companies to Work for in Asia recognised outstanding companies that have demonstrated resilience, adaptability and commitment to people-first...
Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'
Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments Highlighted clinical cases that improved the safety of anti-amyloid therapy...
A New Chapter in Fire Protection: Sungrow SBH Series Passes the World's First UL Solutions' Residential Fire Test
HEFEI, China, Nov. 27, 2025 /PRNewswire/ -- As residential energy storage systems become increasingly prevalent, safety has emerged as a top priority for homeowners. Any incident in a residential setting can lead to serious consequences, and recent...
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily...